Iowa New Jobs Training Program Annual Report, 2003

Iowa New Jobs Training Program Annual Report produced by Economic Developement

F-1, Food Assistance Program State Summary, November 2004

Food Assistance Program State Summary

A-1A Supplemental Security Income Program, November 2004

Supplemental Security Income Program

A-1 Monthly Public Assistance Statistical Report Family Investment Program, November 2004

Monthly Public Assistance Statistical Report Family Investment Program

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.

Purpose: Invasion and migration are key processes of glioblastoma and are tightly linked to tumor recurrence. Integrin inhibition using cilengitide has shown synergy with chemotherapy and radiotherapy in vitro and promising activity in recurrent glioblastoma. This multicenter, phase I/IIa study investigated the efficacy and safety of cilengitide in combination with standard chemoradiotherapy in newly diagnosed glioblastoma. Patients and Methods: Patients (age >= 18 to >= 70 years) were treated with cilengitide (500 mg) administered twice weekly intravenously in addition to standard radiotherapy with concomitant and adjuvant temozolomide. Treatment was continued until disease progression or for up to 35 weeks. The primary end point was progression-free survival (PFS) at 6 months. Results: Fifty-two patients ( median age, 57 years; 62% male) were included. Six- and 12-month PFS rates were 69% (95% CI, 54% to 80%) and 33% ( 95% CI, 21% to 46%). Median PFS was 8 months ( 95% CI, 6.0 to 10.7 months). Twelve- and 24-month overall survival ( OS) rates were 68% ( 95% CI, 53% to 79%) and 35% ( 95% CI, 22% to 48%). Median OS was 16.1 months ( 95% CI, 13.1 to 23.2 months). PFS and OS were longer in patients with tumors with O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation (13.4 and 23.2 months) versus those without MGMT promoter methylation (3.4 and 13.1 months). The combination of cilengitide with temozolomide and radiotherapy was well tolerated, with no additional toxicity. No pharmacokinetic interactions between temozolomide and cilengitide were identified. Conclusion: Compared with historical controls, the addition of concomitant and adjuvant cilengitide to standard chemoradiotherapy demonstrated promising activity in patients with glioblastoma with MGMT promoter methylation. J Clin Oncol 28:2712-2718. (C) 2010 by American Society of Clinical Oncology

A-1 Monthly Public Assistance Statistical Report Family Investment Program, December 2004

A-1 Monthly Public Assistance Statistical Report Family Investment Program

F-1 Food Assistance Program State Summary, December 2004

Food Assistance Program State Summary

A-1 Monthly Public Assistance Statistical Report Family Investment Program, January 2005

A1-Monthly Public Assistance Statistical Report Family Investment Program

F-1 Food Assistance Program State Summary, January 2005

The Food Assistance Monthly Participation Report is a monthly summary of Food Assistance program participation, Statewide and for each Iowa county. Breakouts are reported for participants also in the FIP program, those only receiving Food Assistance, and those that are receiving economic assistance under other programs (primarily Medicaid). This report may also be known as the F-1 Report.

A Review of the State of Iowa Procurement Card Program, For the Period July 1, 2000 through June 30, 2003

Other Audit Reports - Performance Investigation

A-1 Monthly Public Assistance Statistical Report Family Investment Program, February 2005

Monthly Public Assistance Statistical Report Family Investment Program

F-1 Food Assistance Program State Summary, February, 2005

The Food Assistance Monthly Participation Report is a monthly summary of Food Assistance program participation, Statewide and for each Iowa county. Breakouts are reported for participants also in the FIP program, those only receiving Food Assistance, and those that are receiving economic assistance under other programs (primarily Medicaid). This report may also be known as the F-1 Report.

A-1A Supplemental Security Income Program, February 2005

Supplemental security income program

A-1A Supplemental Security Income Program, December 2004

SUPPLEMENTAL SECURITY INCOME PROGRAM

A-1A Supplemental Security Income Program, January 2005

A-1A Supplemental Security Income Program, January 2005